Morphine undermines recovery of function after SCI: Neurobiological mechanisms

吗啡会破坏 SCI 后功能的恢复:神经生物学机制

基本信息

  • 批准号:
    8234030
  • 负责人:
  • 金额:
    $ 29.3万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-03-01 至 2015-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Morphine is one of the most frequently prescribed analgesics for the treatment of neuropathic pain after a spinal cord injury (SCI). Despite widespread use, there has been very little research on the secondary consequences of morphine administration in a spinal injury model. Unfortunately, our research suggests that the acute administration of morphine after SCI has secondary effects that reduce recovery of locomotor function, exacerbate neuropathic pain symptoms, and increase lesion size in the chronic phase of a contusion injury. These data underscore the need for further research on the effects of opioids in a SCI model. To address this issue, we will investigate the molecular consequences of morphine administration after a spinal contusion injury. Three aims are proposed. First, we will examine the role of spinal processes using agonists and antagonists (co-administered with intrathecal morphine) for classic and non-classic opioid receptors. In other models, three receptor systems have been implicated in the direct effects of morphine, including a) the m- opioid receptor, b) the k-opioid receptor, and c) non-classic opioid receptors on glia. The experiments proposed here aim to directly investigate the contribution of these receptor systems, and the role of 'overexcitation' of neural circuitry, in the morphine-induced attenuation of function after SCI. Our working hypothesis is that morphine produces antinociception (pain inhibition) through activation of classic m-opioid receptors on neurons. At compromised spinal loci, however, activation of k-opioid and glial non-classic opioid receptors may potentiate inflammatory responses and overexcitation, intrinsic to the acute phase of spinal injury, and undermine the plasticity of the neural system as well as increase cell death. Secondly, we aim to modulate spinal molecular changes, to protect functional recovery, while using a clinically relevant systemic route of morphine administration to produce analgesia. We hypothesize that we can block the effects of morphine at the spinal level using k-opioid receptor antagonists, or minocycline to block non-classic opioid activation of glia. We will also test the effects of overexcitation by blocking spinal NMDA receptor function with MK-801. Finally, we will identify cellular changes inherent to the contusion injury itself, and those produced though activation of classic and/or non-classic opioid receptors. For this third aim, we plan to target specific receptor systems, and use a cluster analysis to ascertain which molecular end-points co-vary with specific consequences of morphine administration. This proposal innovatively couples modern discoveries in opioid pharmacology with research on spinal cord injury. Most importantly, it will allow us to identify pharmacological interventions that block the adverse effects of opioids at a spinal level, while increasing morphine's beneficial (antinociceptive) effects after SCI. PUBLIC HEALTH RELEVANCE: Morphine undermines recovery of function after SCI: Deriving molecular mechanisms Project Narrative Morphine is one of the most effective and most commonly prescribed analgesics for the treatment of neuropathic pain after a spinal cord injury (SCI). Unfortunately, however, recent research suggests that morphine may have adverse secondary effects after SCI, attenuating the recovery of locomotor function, increasing tissue loss, and producing symptoms of paradoxical pain in the chronic stages of injury. To improve the safety and analgesic efficacy of opioids used after SCI, the proposed experiments will 1) identify critical molecular changes that underlie morphine's effects, 2) use pharmacological manipulations to block adverse effects (reduced recovery, tissue loss) at a spinal level, and potentiate morphine's beneficial (analgesic) effects, and 3) further understanding of the causal molecular mechanisms in neuropathic pain.
描述(由申请人提供):吗啡是治疗脊髓损伤(SCI)后神经性疼痛的最常用处方镇痛药之一。尽管广泛使用,但在脊髓损伤模型中对吗啡给药的继发性后果的研究很少。不幸的是,我们的研究表明,脊髓损伤后急性吗啡给药具有继发性影响,减少运动功能的恢复,加重神经性疼痛症状,并增加挫伤慢性期的病变大小。这些数据强调需要进一步研究阿片类药物在SCI模型中的作用。为了解决这个问题,我们将研究脊髓挫伤后吗啡给药的分子后果。提出了三个目标。首先,我们将使用经典和非经典阿片受体的激动剂和拮抗剂(与鞘内吗啡共同给药)研究脊髓过程的作用。在其他模型中,三种受体系统与吗啡的直接作用有关,包括a)m-阿片受体,B)k-阿片受体,和c)神经胶质上的非经典阿片受体。这里提出的实验旨在直接调查这些受体系统的贡献,以及“过度兴奋”的神经回路的作用,在脊髓损伤后吗啡诱导的功能衰减。我们的工作假设是,吗啡通过激活神经元上的经典m-阿片受体产生抗伤害感受(疼痛抑制)。然而,在受损的脊髓位点,k-阿片样物质和神经胶质非经典阿片样物质受体的激活可能会增强脊髓损伤急性期固有的炎症反应和过度兴奋,破坏神经系统的可塑性以及增加细胞死亡。其次,我们的目标是调节脊髓分子的变化,以保护功能恢复,同时使用临床相关的全身吗啡给药途径产生镇痛。我们假设,我们可以在脊髓水平使用K-阿片受体拮抗剂阻断吗啡的作用,或米诺环素阻断神经胶质细胞的非经典阿片激活。我们还将通过用MK-801阻断脊髓NMDA受体功能来测试过度兴奋的影响。最后,我们将确定挫伤本身固有的细胞变化,以及通过激活经典和/或非经典阿片受体产生的细胞变化。对于这第三个目标,我们计划针对特定的受体系统,并使用聚类分析,以确定哪些分子终点与吗啡给药的特定后果共变。这项提案创新地将阿片类药物药理学的现代发现与脊髓损伤的研究结合起来。最重要的是,它将使我们能够确定在脊髓水平阻断阿片类药物的不良作用的药理学干预,同时增加SCI后吗啡的有益(抗伤害)作用。 公共卫生相关性:吗啡破坏脊髓损伤后的功能恢复:推导分子机制项目叙述吗啡是治疗脊髓损伤(SCI)后神经性疼痛最有效和最常用的止痛药之一。然而,不幸的是,最近的研究表明,吗啡可能有不利的脊髓损伤后的继发性影响,衰减运动功能的恢复,增加组织损失,并在损伤的慢性阶段产生反常疼痛的症状。为了提高SCI后使用阿片类药物的安全性和镇痛效果,拟议的实验将1)确定吗啡作用的关键分子变化,2)使用药理学操作来阻断脊髓水平的不良反应(恢复减少,组织损失),并增强吗啡的有益(镇痛)作用,以及3)进一步了解神经性疼痛的因果分子机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHELLE A HOOK其他文献

MICHELLE A HOOK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHELLE A HOOK', 18)}}的其他基金

Morphine undermines recovery of function after SCI: Neurobiological mechanisms
吗啡会破坏 SCI 后功能的恢复:神经生物学机制
  • 批准号:
    8617260
  • 财政年份:
    2011
  • 资助金额:
    $ 29.3万
  • 项目类别:
Morphine undermines recovery of function after SCI: Neurobiological mechanisms
吗啡会破坏 SCI 后功能的恢复:神经生物学机制
  • 批准号:
    8086576
  • 财政年份:
    2011
  • 资助金额:
    $ 29.3万
  • 项目类别:
Morphine undermines recovery of function after SCI: Neurobiological mechanisms
吗啡会破坏 SCI 后功能的恢复:神经生物学机制
  • 批准号:
    8426179
  • 财政年份:
    2011
  • 资助金额:
    $ 29.3万
  • 项目类别:
Paviovian Conditioning of Injured Spinal Cord Systems
受损脊髓系统的帕维奥调理
  • 批准号:
    7162156
  • 财政年份:
    2006
  • 资助金额:
    $ 29.3万
  • 项目类别:
Paviovian Conditioning of Injured Spinal Cord Systems
受损脊髓系统的帕维奥调理
  • 批准号:
    7030106
  • 财政年份:
    2006
  • 资助金额:
    $ 29.3万
  • 项目类别:
The Effects of Morphine on Sensory and Motor Functions After A Spinal Cord Injury
吗啡对脊髓损伤后感觉和运动功能的影响
  • 批准号:
    7017164
  • 财政年份:
    2005
  • 资助金额:
    $ 29.3万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.3万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 29.3万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.3万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.3万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.3万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.3万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.3万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 29.3万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 29.3万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 29.3万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了